Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (11-20 of 198) with videos related to

Pageof 20
Sort By:
Lancet (London, England)|February 10, 2020
Inhibition of interleukins 17A and 17F in psoriatic arthritisPeter Nash
The Journal of Rheumatology|March 16, 2022
Janus Kinase Inhibitors: Safety in Patients With Psoriatic ArthritisPeter Nash
Rheumatology (Oxford, England)|February 18, 2026
What's new in the BSR csDMARDs 2025 guideline update?Peter Nash
Rheumatology (Oxford, England)|October 23, 2023
Comorbidities in RA: bringing them to the limelightElena Nikiphorou, Peter Nash
Nursing Times|February 5, 2016
Learning disabilities: improved bowel screeningMandy Bowler, Peter Nash
Nursing Times|June 26, 2014
Professional boundaries in learning disability careMandy Bowler, Peter Nash
International Journal of Rheumatic Diseases|April 9, 2010
The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapyGeoff Strange, Peter Nash
Best Practice & Research. Clinical Rheumatology|August 21, 2019
Practical issues in the modern management of rheumatic diseaseJoseph Markenson, Peter Nash
Best Practice & Research. Clinical Rheumatology|September 26, 2025
Novel TherapyMitsumasa Kishimoto, Peter Nash
International Journal of Rheumatic Diseases|January 3, 2014
Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey studyPeter Nash, Dave Nicholls
Pageof 20

Showing results (11-20 of 198) with videos related to

Sort By:
Pageof 20
Lancet (London, England)|February 10, 2020
Inhibition of interleukins 17A and 17F in psoriatic arthritisPeter Nash
The Journal of Rheumatology|March 16, 2022
Janus Kinase Inhibitors: Safety in Patients With Psoriatic ArthritisPeter Nash
Rheumatology (Oxford, England)|February 18, 2026
What's new in the BSR csDMARDs 2025 guideline update?Peter Nash
Rheumatology (Oxford, England)|October 23, 2023
Comorbidities in RA: bringing them to the limelightElena Nikiphorou, Peter Nash
Nursing Times|February 5, 2016
Learning disabilities: improved bowel screeningMandy Bowler, Peter Nash
Nursing Times|June 26, 2014
Professional boundaries in learning disability careMandy Bowler, Peter Nash
International Journal of Rheumatic Diseases|April 9, 2010
The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapyGeoff Strange, Peter Nash
Best Practice & Research. Clinical Rheumatology|August 21, 2019
Practical issues in the modern management of rheumatic diseaseJoseph Markenson, Peter Nash
Best Practice & Research. Clinical Rheumatology|September 26, 2025
Novel TherapyMitsumasa Kishimoto, Peter Nash
International Journal of Rheumatic Diseases|January 3, 2014
Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey studyPeter Nash, Dave Nicholls
Pageof 20